Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 6
2016 5
2017 4
2018 3
2019 2
2020 4
2021 15
2022 10
2023 8
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy-associated Autoimmune Hemolytic Anemia.
Hwang SR, Saliba AN, Wolanskyj-Spinner AP. Hwang SR, et al. Among authors: saliba an. Hematol Oncol Clin North Am. 2022 Apr;36(2):365-380. doi: 10.1016/j.hoc.2021.11.002. Hematol Oncol Clin North Am. 2022. PMID: 35339260 Review.
Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN, Gangat N. Saliba AN, et al. Best Pract Res Clin Haematol. 2022 Jun;35(2):101379. doi: 10.1016/j.beha.2022.101379. Epub 2022 Aug 30. Best Pract Res Clin Haematol. 2022. PMID: 36333070 Review.
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
Csizmar CM, Saliba AN, Swisher EM, Kaufmann SH. Csizmar CM, et al. Among authors: saliba an. Cancers (Basel). 2021 Dec 20;13(24):6385. doi: 10.3390/cancers13246385. Cancers (Basel). 2021. PMID: 34945003 Free PMC article. Review.
Iron overload in thalassemia: different organs at different rates.
Taher AT, Saliba AN. Taher AT, et al. Among authors: saliba an. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):265-271. doi: 10.1182/asheducation-2017.1.265. Hematology Am Soc Hematol Educ Program. 2017. PMID: 29222265 Free PMC article. Review.
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Saliba AN, et al. Blood Adv. 2023 Jun 13;7(11):2360-2363. doi: 10.1182/bloodadvances.2022008625. Blood Adv. 2023. PMID: 36315007 Free PMC article. Clinical Trial. No abstract available.
54 results